Literature DB >> 25946711

Induction of homologous and cross-reactive GII.4-specific blocking antibodies in children after GII.4 New Orleans norovirus infection.

Vesna Blazevic1, Maria Malm1, Timo Vesikari1.   

Abstract

Noroviruses (NoVs) are major causative agents of acute gastroenteritis (AGE) in children worldwide and the most common viral cause of AGE in countries where rotavirus incidence has been eliminated by vaccination. Previous infections with the dominant GII.4 NoV genotype confer only partial protection against evolving immune escape variants that emerge every few years. The objective of this work was to investigate GII.4-specific homologous and cross-reactive antibody responses in young children after NoV GII.4-2009 New Orleans (NO) infection. Virus-like particles (VLPs) representing GII.4-1999, GII.4-2009 NO, and GII.4-2012 Sydney genotypes were used in ELISA and histo-blood group antigen blocking assays to examine acute and convalescent sera of five children <2 years of age infected with GII.4-2009 NO. GII.4-2009 NO infection induced IgG seroconversion to all three tested NoV GII.4 variants. Homologous blocking antibodies to GII.4-2009 NO were detected in each convalescent sera. Fourfold increase in cross-blocking antibodies to GII.4-2012 Sydney was observed in 4/5 subjects, but no child developed cross-blocking antibodies to GII.4-1999. In conclusion, antibodies induced in young children after norovirus GII.4 infection are targeted against the causative variant and may cross-protect against strains that are closely related, but not with more distinct and earlier GII.4 genotypes.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  IgG; blocking antibodies; cross-protection; immune responses; norovirus GII.4

Mesh:

Substances:

Year:  2015        PMID: 25946711     DOI: 10.1002/jmv.24237

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  8 in total

1.  Human VP8* mAbs neutralize rotavirus selectively in human intestinal epithelial cells.

Authors:  Ningguo Feng; Liya Hu; Siyuan Ding; Mrinmoy Sanyal; Boyang Zhao; Banumathi Sankaran; Sasirekha Ramani; Monica McNeal; Linda L Yasukawa; Yanhua Song; B V Venkataram Prasad; Harry B Greenberg
Journal:  J Clin Invest       Date:  2019-08-12       Impact factor: 14.808

Review 2.  Norovirus vaccines: Correlates of protection, challenges and limitations.

Authors:  Nada M Melhem
Journal:  Hum Vaccin Immunother       Date:  2016-02-02       Impact factor: 3.452

Review 3.  The Antigenic Topology of Norovirus as Defined by B and T Cell Epitope Mapping: Implications for Universal Vaccines and Therapeutics.

Authors:  Jessica M van Loben Sels; Kim Y Green
Journal:  Viruses       Date:  2019-05-10       Impact factor: 5.048

4.  Simultaneous Immunization with Multivalent Norovirus VLPs Induces Better Protective Immune Responses to Norovirus Than Sequential Immunization.

Authors:  Maria Malm; Timo Vesikari; Vesna Blazevic
Journal:  Viruses       Date:  2019-11-02       Impact factor: 5.048

5.  Humoral and Mucosal Immune Responses to Human Norovirus in the Elderly.

Authors:  Veronica P Costantini; Emilie M Cooper; Hope L Hardaker; Lore E Lee; Emilio E DeBess; Paul R Cieslak; Aron J Hall; Jan Vinjé
Journal:  J Infect Dis       Date:  2020-05-11       Impact factor: 5.226

6.  Norovirus-Specific Memory T Cell Responses in Adult Human Donors.

Authors:  Maria Malm; Kirsi Tamminen; Timo Vesikari; Vesna Blazevic
Journal:  Front Microbiol       Date:  2016-10-03       Impact factor: 5.640

7.  Virus-Host Interactions Between Nonsecretors and Human Norovirus.

Authors:  Lisa C Lindesmith; Paul D Brewer-Jensen; Michael L Mallory; Kara Jensen; Boyd L Yount; Veronica Costantini; Matthew H Collins; Caitlin E Edwards; Timothy P Sheahan; Jan Vinjé; Ralph S Baric
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2020-04-11

Review 8.  Serological Humoral Immunity Following Natural Infection of Children with High Burden Gastrointestinal Viruses.

Authors:  Mark R Zweigart; Sylvia Becker-Dreps; Filemón Bucardo; Fredman González; Ralph S Baric; Lisa C Lindesmith
Journal:  Viruses       Date:  2021-10-09       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.